

Gillian A Horne

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2270693/gillian-a-horne-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

13
papers

92
citations

5
h-index

9
g-index

14
ext. papers

166
ext. citations

7.8
avg, IF

2.45
L-index

#	Paper	IF	Citations
13	Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial.. <i>Lancet Haematology,the</i> , 2021 ,	14.6	2
12	Implications of CAR-T cell therapy on apheresis services: a Scottish perspective. <i>Journal of Clinical Apheresis</i> , 2021 , 36, 513-515	3.2	1
11	Multiple myeloma: therapeutic delivery of antibodies and aptamers. <i>Therapeutic Delivery</i> , 2021 , 12, 705-722	3.2	1
10	Synergistic cytotoxicity of dual PI3K/mTOR and FLT3 inhibition in FLT3-ITD AML cells. <i>Advances in Biological Regulation</i> , 2021 , 82, 100830	6.2	0
9	A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease. <i>Leukemia</i> , 2020 , 34, 1775-1786	10.7	26
8	CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy. <i>Leukemia</i> , 2020 , 34, 1613-1625	10.7	22
7	Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	20
6	The psychological impact of COVID19 on a shielding high-risk cohort. <i>Scottish Medical Journal</i> , 2020 , 65, 120-122	1.8	2
5	Trial re-investment to build better research for better impact. <i>Lancet, The</i> , 2019 , 394, 635-636	40	1
4	Approaches for targeting self-renewal pathways in cancer stem cells: implications for hematological treatments. <i>Expert Opinion on Drug Discovery</i> , 2017 , 12, 465-474	6.2	7
3	Notch Pathway Activation Targets Leukemic Stem Cells in Chronic-Phase Chronic Myeloid Leukemia (CP-CML). <i>Blood</i> , 2016 , 128, 3057-3057	2.2	1
2	Haemolytic anaemia: don't leave it out in the cold. <i>Archives of Disease in Childhood: Education and Practice Edition</i> , 2015 , 100, 323-30	0.5	
1	CD93 Is a Novel Biomarker of Leukemia Stem Cells in Chronic Myeloid Leukemia. <i>Blood</i> , 2015 , 126, 49-49	2.2	7